10th annual Pharma IPR India meet concludes

Hyderabad The three-day 10th annual Pharma IPR India Conference conducted in virtual mode in collaboration with Informa Pharma Intelligence, has concluded. The meet was organised with a dynamic theme of 'Ideate and Innovate'. The programme was held from September 22 to September 24.

The event witnessed innovative exchange of thoughts with an aim to create an efficient IP framework globally to bolster the potential of growth, investments, and collaboration amid crises.

"The Indian pharma Industry has generated remarkable growth in the past decades fueled by increasing burden of diseases and our aspirations to be the key generics, biosimilar and vaccine manufacturer for the world markets. With the increasing need for developing new and novel drug therapies, biosimilars and value-added generics, and intellectual property, play a crucial role in protecting these innovations and novel formulations."

Yogesh Mudras, Managing Director, Informa Markets in India, said, "The pharmaceutical sector is complex and highly regulated in most economies. Recent challenges over patents for varied newer drugs has emphasised that advancement is still required in balancing the opposing forces of innovation through protection of IP rights, versus the provision of affordable drugs for the emerging geographical regions across the globe. IP is the backbone to ensure development of new drugs and is extremely vital to improvise patient care, spurring economic growth and intensifying the innovation economy. To motivate researchers to explore new areas of medical innovation, modern IP systems and strong protections are crucial. With this broad vision in mind, we are proud to present the Annual Pharma IPR Conference this year.

Amongst the notable members of the advisory board and speakers were Prathiba M Singh, Judge, Delhi High Court, Jacqueline Wright Bonilla, Deputy Chief Administrative Patent Judge, Patent Trial and Appeal Board (PTAB), US Patent and Trademark Office.

Representatives of pharma companies such as, Biocon, Zydus Cadilla, Wockhardt, Glenmark Pharmaceuticals, Dr. Reddy's, Sun Pharma, Mankind Pharma, Neuland Labs & Abbott Healthcare etc. shared insights on the emerging markets and key learnings for IP fraternity, notable global developments, amendments, and proposals to amendments at legislative, policy and regulatory side along with latest updates on Covid 19 patent waiver emerging global consensus.